Beamtree Holdings Ltd · ASX:BMT
Beamtree — Investor Presentation (February 2023)
32 slides from Beamtree's investor presentation, Feb 15, 2023
Slide 1: 1H FY23 Annual Results
1H FY23 Annual Results 15th February, 2023
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 15 February 2023. This presentation may contain statements that are, or may be deemed to be, forward looking s
Slide 3: 1H FY23 Highlights
1H FY23 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: 1H FY23 Financial Highlights
1H FY23 Financial Highlights 20% PCP* 47% 55% 37% PCP PCP PCP Annual recurring Reported International Operating Profit Cash Revenue Revenue Revenue $20.1M $10.5M $3.2M $(0.9)M $5.4M 1H FY23 operating loss +$3.6m improvement 98% recurring of $0.9m vs 1H FY22 in net cash outflow revenue vs 87% in loss
Slide 5: 1H FY23 Key Strategic Highlights
1H FY23 Key Strategic Highlights Renewal of RippleDown® product distribution contract with Abbott Laboratories for a minimum of 3 years with improved pricing for Beamtree and enhanced focus within Abbott on the RippleDown® product. Revised contract term with our largest client, Health Roundtable, se
Slide 6: FY23 Outlook
FY23 Outlook Management reaffirms long term outlook of delivering annual recurring revenue of $60m by 2026. FY23 organic recurring revenue growth forecast to be ~20% consistent with 1H trading. Forecast to deliver several strategic international projects in 2H to accelerate growth going into FY24. C
Slide 7: Long Term Outlook – No change
Long Term Outlook – No change Main Drivers of Growth: ~70% of the growth will come from overseas market ARR $60M ▪ Abbott (3+2 year) contract with revenue share 35% CAGR ~35-40% ▪ International direct RippleDown® sales ARR $20M ~15-20% ▪ Sales of CDS (Ainsoff AI) products both in ANZ and ~15-20% Int
Slide 8: Beamtree Strategy
Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 7
Slide 9: Creating a better future for health
Creating a better future for health We provide AI decision support and data insights solutions with the aim of turning data into insights and action through automation. We believe it starts with better data and ends in better care – and that ‘better has no limit’
Slide 10: About Us
me Australian company with Supporting healthcare Cutting-edge use of Al Australian IP globally and machine learning kan | </> AS LQ. == 40% nti! Diagnostic Technology _ Clinical Decision Support | Coding Assistance & Analytics & Knowledge leaders in acute care Data Quality Networks
Slide 11: Beamtree’s History
Beamtree’s History Pacific Knowledge Systems ¢ Est. 1999 - Listed 2019 RippleDown —-RippleDown’ Auditor Expert, Ainsoff Est. 2018 - Acq. 2021 ISAT AB
Slide 12: Supporting Healthcare Providers Globally
Supporting Healthcare Providers Globally
Slide 13: Learning Health Systems
Learning Health Systems Driving continuous improvement by better access to healthcare information — towards safety, quality a
Slide 14: The Problems We Help Solve
The Problems We Help Solve Ce Tackle unwarranted Offer revenue Promote transparency variation assurance Address equity Bridge knowledge gaps Increase efficiency, of access and resource reducing mistakes allocation Drive automation (\\ A Improve quality of data
Slide 15: Our product segments
Our product segments Coding Assistance and Data Quality Diagnostic Technology Digitising and automating workflows with data, Enabling the effective delivery of diagnostic classification, coding & technical expertise to services as they underpin the future of health improve information standardisatio
Slide 16: Key Areas, Key Products and What They Do
Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Leverages scarce clinical Removes duplication Recurring Clinical rules to automate resources through for experts in License + volume expert decision making in Diagnostics automating and providing
Slide 17: 1H Operational Highlights
1H Operational Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 16
Slide 18: Highlights of 1H FY23
Highlights of 1H FY23 Health Roundtable’s (HRT's) “Better Together: Advancing Quality Outcomes” workshop Agreement from HRT Board to begin technology PICQ*s DRG Change Report released providing insight $s sane he pai modernisation program into the financial benefits of coding quality review Global H
Slide 19: Key Operational Highlights
Key Operational Highlights Product/ Solutions 1H Operational Highlights Going Forward • Signed new distribution contract with Abbott Laboratories and issued 9 new licences in the first half • ~30% of FY22 revenue • Continued implementation of RippleDown® into large pathology provider in • Focus on i
Slide 20: 1H FY23 Strategic Partnerships
1H FY23 Strategic Partnerships Abbott Health Roundtable • Signed Dec 2022, 3 year contract with 2 x1 • Revised contract terms agreed in January year extension options 2023 • Global distribution contract, direct sales by • Mid contract termination option removed to Beamtree still permitted deliver a
Slide 21: 1H FY23 Strategic Partnerships
1H FY23 Strategic Partnerships Lean (Kingdom of Saudi Arabia) Milton Keynes (UK) • Signed partnership agreement Oct 2022 • Signed in January 2023 • Parties to work together to deliver • Agreement to form a first-in-kind centre of automation and better data quality to excellence to promote AI and aut
Slide 22: 1H FY23 Financial Results
1H FY23 Financial Results Copyright © Beamtree Holdings Limited – All Rights Reserved 21
Slide 23: Annual Recurring Revenue (ARR) Growth
Annual Recurring Revenue* (ARR) Growth ($’M) +158% PCP +20% (+17% organic PCP) organic PCP 3.3 • +20% PCP organic growth in Annual 1.1 Recurring Revenue (ARR) largely driven by international growth. 9.2 20.1 • Almost 60% of organic ARR growth was 16.8 driven by our Diagnostics segment with the remai
Slide 24: 1H Reported Revenue Growth
1H Reported Revenue Growth ($’M) Comments +47% PCP (+24% organic • +47% PCP growth in Reported revenue in PCP) 1H FY23 has been driven by $2.7m from Knowledge Networks (Potential(x) +91% PCP 1.5 (+2% organic acquisition) and $1.5m organic revenue PCP) growth. All of this organic revenue 2.7 growth i
Slide 25: 1H Operating Expenses & Investments
1H Operating Expenses & Investments ($’M) +4.5% Annual organic growth rate 11.4 10.9 0.5 2.4 8.5 1H FY22 Potential (x) acquisition 1H FY22 LFL Organic costs increase 1H FY23 $2.9m operating expenses increase has been mainly driven by acquisition impact from Potential(x) in Oct 2021 (3 months costs i
Slide 26: Revenue & Operating Profit Trend and EBITDA
Revenue & Operating Profit Trend and EBITDA Reported revenue and operating profit ($M) Operating Profit to reported EBITDA ($M) +47% PCP Reported revenue 1H FY21 1H FY22 1H FY23 Operating Profit 0.5 (1.4) (0.9) 9.4 10.5 Non operating expenses (cash) 7.1 Transaction cost 0.0 (0.1) 0.0 3.7 4.7 Impact
Slide 27: 1H Summary Profit and Loss
1H Summary Profit and Loss 1H FY23 1H FY22 Change Organic Highlights P&L ($M) Actual Actual 1H FY23 - 1H FY22 Growth % Group Revenue 47% Revenue 10.5 7.1 47% Annual recurring revenue (ARR) 20.1 16.8 20% +20% Expenses – staff (8.0) (5.7) 39% Expenses – non staff (3.4) (2.8) 21% Total operating expens
Slide 28: 1H Cashflow
1H Cashflow 1H FY23 1H FY22 1H FY23 Comments CONSOLIDATED GROUP ($M) Actual Actual CASHFLOWS FROM OPERATING ACTIVITIES Receipts from customers Payments to suppliers and employees 13.4 (12.9) 6.6 (8.9) $0.5M Other receipts/(paid) 0.0 0.0 Operating net cash Net cash provided by operating activities 0.
Slide 29: Executive Summary 1H FY23 Highlights
Executive Summary 1H FY23 Highlights Annual recurring 1H Reported 1H International Revenue Revenue Revenue $20.1M $10.5M $3.2M 20% 47% 55% PCP* PCP PCP 1H Operating 1H Positive 1H Net cash profit operating cash flow improvement vs. 1H FY22 excl $(0.9)M acquisition +$0.5M +0.5M +$3.6M PCP Prior Corre
Slide 30: Thank you
Thank you Copyright © Beamtree Holdings Limited – All Rights Reserved 29
Slide 31: Appendices
Appendices Copyright © Beamtree Holdings Limited – All Rights Reserved 30
Slide 32: Balance Sheet
Balance Sheet 1H FY23 1H FY22 CONSOLIDATED GROUP ($M) Actual Actual Current assets Cash & cash equivalents 5.4 7.0 Comments Trade & other receivables 5.0 5.2 Contracts 0.0 0.5 $5.4m cash balance Total current assets 10.4 12.7 Non current assets Property plant & equipment 0.3 0.7 Right of use assets
Beamtree Holdings — Investor Presentation (February 2023) on 6ix